drugset / Trial / NCT06598839
Immuno-effect of Tα1 for Stage I NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2024-06-30
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymalfasin | Peptide | 1.6 mg | Subcutaneous |